Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.30 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8181587 | 0.90 | SLC6A1 (0.39) | EP300SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL27462344 | 0.90 | SLC6A1 (0.39) | EP300SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL5548176 | 0.83 | NR1H2 (0.36) | — | |
| SCHEMBL5969013 | 0.83 | — | — | |
| SCHEMBL5549776 | 0.80 | — | — | |
| SCHEMBL5335883 | 0.80 | — | — | |
| SCHEMBL8327465 | 0.78 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL8470081 | 0.78 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL5969125 | 0.78 | SLC6A1 (0.37) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL7275858 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931078-B1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-6984627-B1 | Peptide derivatives | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-20050222395-A1 | New peptide derivatives | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-0701568-B1 | NEW PEPTIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-25 | — | — | EP | disclosed |
| EP-1067136-A1 | New peptide derivatives | AstraZeneca AB (SE) | 2001-01-10 | — | — | EP | disclosed |
| CN-1278530-A | Novel peptide derivative | ASTRA AB (SE) | 2001-01-03 | — | — | CN | disclosed |
| US-5965570-A | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING THE ABNORMAL GROWTH OF CELLS; ADMINISTERING TO INHIBIT TUMOR CELLS WHEREIN THE RAS PROTEIN IS ACTIVATED AS A RESULT OF ONCOGENIC MUTATION IN GENES OTHER THAN THE RAS GENE | SCHERING CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5939392-A | THROMBIN INHIBITORS, ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | ASTRA AKTIEBOLAG (SE) | 1999-08-17 | — | — | US | disclosed |
| EP-0931078-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-07-28 | — | — | EP | disclosed |
| US-5856307-A | Peptide derivatives as kininogenase inhibitors | ASTRA AKTIEBOLAG (SE) | 1999-01-05 | — | — | US | disclosed |
| US-5783563-A | Method for treatment or prophylaxis of venous thrombosis | ASTRA AKTIEBOLAG | 1998-07-21 | — | — | US | disclosed |
| US-5780631-A | ANTICOAGLUANT | ASTRA AKTIEBOLAG (SE) | 1998-07-14 | — | — | US | disclosed |
| WO-1998011098-A1 | NOVEL TRICYCLIC PIPERIDINYL COMPOUNDS USEFUL AS INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-03-19 | — | — | WO | disclosed |
| US-5723444-A | ENZYME INHIBITORS AND ANTICOAGULANTS | ASTRA AB (SE) | 1998-03-03 | — | — | US | disclosed |
| US-5602253-A | STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222395-A1 | New peptide derivatives | SERPINE1, SERPINC1, SPINT2 | EP300 4000/4885ANPEP 75/4885ERAP2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.